Eledon Pharma Files Q1 2025 10-Q, Details R&D
Ticker: ELDN · Form: 10-Q · Filed: May 14, 2025 · CIK: 1404281
| Field | Detail |
|---|---|
| Company | Eledon Pharmaceuticals, Inc. (ELDN) |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, R&D, filing
TL;DR
Eledon Pharma Q1 10-Q filed. R&D expenses noted. Check for financing details.
AI Summary
Eledon Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported research and development expenses for the first quarter of 2025. The filing also references a Securities Purchase Agreement from May 5, 2023, and a license agreement with the ALS Therapy Development Foundation, Inc. dated January 1, 2023.
Why It Matters
This filing provides insight into Eledon Pharmaceuticals' financial activities and ongoing research and development efforts for the first quarter of 2025, which can impact investor understanding of the company's progress.
Risk Assessment
Risk Level: medium — The filing indicates ongoing R&D and past financing activities, which are typical for a pharmaceutical company, but specific financial health details beyond R&D expenses are not immediately apparent in this snippet.
Key Numbers
- Q1 2025 — Reporting Period (First quarter of 2025)
- 20250331 — Fiscal Period End (End date for the reported period)
Key Players & Entities
- Eledon Pharmaceuticals, Inc. (company) — Filer
- 20250331 (date) — Reporting Period End Date
- 20250514 (date) — Filing Date
- Novus Therapeutics, Inc. (company) — Former Company Name
- Tokai Pharmaceuticals Inc (company) — Former Company Name
- 0000950170-25-071582 (document_id) — Accession Number
- ALS Therapy Development Foundation, Inc. (company) — License Agreement Party
- 2023-01-01 (date) — License Agreement Start Date
- 2023-05-05 (date) — Securities Purchase Agreement Date
FAQ
What were Eledon Pharmaceuticals' research and development expenses for the first quarter of 2025?
The filing indicates that 'us-gaap:ResearchAndDevelopmentExpenseMember' was reported for the period '2024-01-01' to '2024-03-31', which corresponds to Q1 2024, not Q1 2025 as stated in the summary. The snippet does not explicitly state Q1 2025 R&D expenses.
When was the Securities Purchase Agreement initially effective?
The filing references a 'SecuritiesPurchaseAgreementInitialClosingMember' associated with the date '2023-05-05'.
What is the nature of the agreement with the ALS Therapy Development Foundation, Inc.?
The filing mentions an 'ALSTherapyDevelopmentFoundationIncLicenseAgreementMember' with a period from '2023-01-01' to '2023-12-31'.
What were the former names of Eledon Pharmaceuticals, Inc.?
Eledon Pharmaceuticals, Inc. was formerly known as Novus Therapeutics, Inc. (name change on 20170511) and prior to that, Tokai Pharmaceuticals Inc (name change on 20070622).
What is the company's primary industry classification?
Eledon Pharmaceuticals, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding Eledon Pharmaceuticals, Inc. (ELDN).